Momentum builds behind AI partnership following last year's announcement of a 5GW UAE–US AI Campus and chip approvals as leaders meet in Davos
DAVOS, Switzerland, Jan. 21, 2026 /PRNewswire/ -- Today, on the sidelines of the World Economic Forum Annual Meeting in Davos, G42 Group CEO Peng Xiao joined David Sacks, White House Advisor on Artificial Intelligence and Cryptocurrency, for a timely discussion on the future of U.S.–UAE AI cooperation and what it will take to compete at scale in the global AI race.
As AI rapidly moves from experimentation to mass adoption, the panel underscored a central reality that AI leadership will be defined by ecosystem partnerships, infrastructure readiness, and access to energy and compute at unprecedented scale. Speaking at the UAE Pavilion, Sacks highlighted the UAE, and G42, as a critical partner in enabling this next phase of AI growth, emphasizing the importance of trusted partners that can deliver gigawatt-scale power and deploy AI on U.S. technology stacks.
From G42's perspective, Xiao shared insights from building and operating AI infrastructure at scale, stressing that trust, execution, and long-term investment are foundational to success. He highlighted the UAE's unique ability to support global AI workloads efficiently from Abu Dhabi, reaching billions of users worldwide with ultra-low latency, and reinforced the role of AI diffusion in sustaining U.S. leadership.
The conversation follows major milestones in U.S.–UAE AI collaboration, including the announcement of a planned 5GW UAE–U.S. AI Campus, the largest outside the United States, and recent U.S. approvals supporting advanced AI compute for G42.
Watch the full conversation to hear how U.S.–UAE AI cooperation is shaping the future of global AI leadership here: https://youtu.be/dF2SollBR_k
About G42
G42 is a technology holding group and a global leader in artificial intelligence, delivering impactful solutions across sectors including government, healthcare, energy, finance, and space. Headquartered in Abu Dhabi and operating worldwide, G42 is building the Intelligence Grid to deliver intelligence on demand, securely and at scale.
For more information, visit www.g42.ai
Media Contact
For more information, please contact: G42@trailrunnerint.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Video: U.S. AI Advisor Sacks Highlights UAE and G42 as Critical Partners in U.S. AI Competitiveness
DEERFIELD, Ill., Jan. 21, 2026 /PRNewswire/ -- Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met with enthusiastic adoption by surgical teams who value convenience, versatility, and clinical performance.
Hemopatch Sealing Hemostat is a ready-to-use, absorbable collagen pad designed for tissue sealing and hemostasis.1 The new room temperature format eliminates the need for refrigeration, streamlining preparation and storage in operating rooms.1 Surgeons across the region are finding significant value in the product's ability to manage mild to moderate bleeding scenarios with confidence.
"Hemopatch Sealing Hemostat is an excellent product that is quite versatile across many urological operations. The ability to handle venous bleeding across wide surfaces is great for patients and has allowed me to confidently use Hemopatch Sealing Hemostat," said Urological Surgeon, A/Prof Matthew Roberts from Queensland, Australia.
Baxter is proud to deliver meaningful value to clinicians through innovations like Hemopatch Sealing Hemostat, and empowering surgical teams in achieving their desired patient outcomes. The product's strong reception underscores our commitment to providing solutions that help save and sustain lives.
With a shelf life of up to 36 months and compatibility with both open and minimally invasive procedures, Hemopatch Sealing Hemostat continues to be a trusted tool in operating rooms across Australia and New Zealand.1
For more information on Hemopatch Sealing Hemostat,
Visit: https://advancedsurgery.baxter.eu/hemopatch
Reference:
Manufacturer:
Baxter Healthcare SA
Thurgauerstrasse 130 Glattbrugg,
ZÜRICH, 8152 Switzerland
Class of Device: III
CE0123
This content is intended solely for healthcare professionals and should not be interpreted as medical advice. Please consult with a qualified healthcare provider for any health concerns.
Hemopatch sealing hemostat is approved for use only in selected countries. For specific information on the availability and regulatory status of Hemopatch sealing hemostat room temperature in your country, we recommend contacting your local Baxter Healthcare sales representative.
Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries.
GBU-AS21-250032 (v1.0) 01/2026
Photo - https://mma.prnasia.com/media2/2859987/Hemopatch_OR.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2859988/HemopatchIRI_AU.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand
Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand
